Table 1. . Baseline demographic and clinical characteristics for patients with glioblastoma multiforme by MGMT promoter testing status.
| Variable | MGMT methylation testing status | |||
|---|---|---|---|---|
| Overall | No | Yes | p-value | |
| Total patient count (n) | 750 | 246 | 504 | |
| Age at diagnosis (years) | 0.2227 | |||
| Patients with available data (n) | 750 | 246 | 504 | |
| Mean, years (SD) | 62.1 (12.4) | 62.9 (12.2) | 61.6 (12.5) | |
| Median, years (min, max) | 63.4 (20.1, 89.6) | 63.8 (22.1, 87.4) | 63.2 (20.1, 89.6) | |
| Age group, n (%) | 0.5595 | |||
| <65 years | 418 (55.7) | 131 (53.3) | 287 (56.9) | |
| ≥65–75 years | 228 (30.4) | 77 (31.3) | 151 (30.0) | |
| >75 years | 104 (13.9) | 38 (15.4) | 66 (13.1) | |
| Sex, n (%) | 0.8779 | |||
| Female | 317 (42.3) | 103 (41.9) | 214 (42.5) | |
| Male | 433 (57.7) | 143 (58.1) | 290 (57.5) | |
| Race, n (%) | 0.8901 | |||
| Caucasian | 597 (79.6) | 209 (85.0) | 388 (77.0) | |
| Black or African–American | 17 (2.3) | 6 (2.4) | 11 (2.2) | |
| Asian | 13 (1.7) | 3 (1.2) | 10 (2.0) | |
| American–Indian or Alaskan native | 3 (0.4) | 1 (0.4) | 2 (0.4) | |
| Unknown | 120 (16.0) | 27 (11.0) | 93 (18.5) | |
| Ethnicity, n (%) | 0.0079 | |||
| Hispanic or Latino | 54 (7.2) | 28 (11.4) | 26 (5.2) | |
| Not Hispanic or Latino | 560 (74.7) | 189 (76.8) | 371 (73.6) | |
| Unknown | 136 (18.1) | 29 (11.8) | 107 (21.2) | |
| Practice region, n (%) | <0.0001 | |||
| South | 394 (52.5) | 142 (57.7) | 252 (50.0) | |
| West | 231 (30.8) | 81 (32.9) | 150 (29.8) | |
| Northeast | 76 (10.1) | 5 (2.0) | 71 (14.1) | |
| Midwest | 49 (6.5) | 18 (7.3) | 31 (6.2) | |
| ECOG PS at diagnosis, n (%) | 0.1798 | |||
| 0 | 44 (5.9) | 14 (5.7) | 30 (6.0) | |
| 1 | 397 (52.9) | 125 (50.8) | 272 (54.0) | |
| 2 | 128 (17.1) | 49 (19.9) | 79 (15.7) | |
| ≥3 | 29 (3.9) | 14 (5.7) | 15 (3.0) | |
| Unknown | 152 (20.3) | 44 (17.9) | 108 (21.4) | |
| Surgery type, n (%) | 0.0008 | |||
| Resection >90% | 15 (2.0) | 5 (2.0) | 10 (2.0) | |
| Resection <90% (not a biopsy) | 15 (2.0) | 2 (0.8) | 13 (2.6) | |
| Resection NOS | 603 (80.4) | 184 (74.8) | 419 (83.1) | |
| Biopsy | 114 (15.2) | 52 (21.1) | 62 (12.3) | |
| No GBM-related surgery | 3 (0.4) | 3 (1.2) | 0 (0.0) | |
| Resection vs biopsy, n (%) | 114 (15.3) | 52 (21.4) | 62 (12.3) | 0.0002 |
| Steroid use prior to 1L treatment, n (%) | 400 (53.3) | 136 (55.3) | 264 (52.4) | 0.5166 |
Bold numbers are p-values indicating significant difference.
1L: First line; ECOG PS: Eastern Cooperative Oncology Group performance status; GBM: Glioblastoma; MGMT: O6-methylguanine-DNA methyltransferase; NOS: Not otherwise specified; SD: Standard deviation.